Uploaded June 2024 | Updated September 2026, 1 week ago
Discover how a groundbreaking collaboration bringing together the Lawrence Livermore National Laboratory (LLNL), BridgeBio Oncology Therapeutics and the Frederick National Laboratory for Cancer Research is helping to revolutionize cancer treatment and computer-aided drug discovery. For the first time in the known history of the Department of Energy, a cancer drug discovered and co-developed through a combination of LLNL’s world-class supercomputing, innovative computational drug discovery methods and industry expertise have led to a novel KRAS-targeting drug for lung cancer that is now undergoing human clinical trials. Learn how this pioneering effort could accelerate the development of new treatments for cancer and other diseases, offering renewed hope for patients worldwide.
Discover how a groundbreaking collaboration bringing together the Lawrence Livermore National Laboratory (LLNL), BridgeBio Oncology Therapeutics and the Frederick National Laboratory for Cancer Research is helping to revolutionize cancer treatment and computer-aided drug discovery. For the first time in the known history of the Department of Energy, a cancer drug discovered and co-developed through a combination of LLNL’s world-class supercomputing, innovative computational drug discovery methods and industry expertise have led to a novel KRAS-targeting drug for lung cancer that is now undergoing human clinical trials. Learn how this pioneering effort could accelerate the development of new treatments for cancer and other diseases, offering renewed hope for patients worldwide.
